View ValuationNanosonics 将来の成長Future 基準チェック /36Nanosonics利益と収益がそれぞれ年間21.2%と8.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に11.9% 20.7%なると予測されています。主要情報21.2%収益成長率20.65%EPS成長率Medical Equipment 収益成長16.1%収益成長率8.6%将来の株主資本利益率11.91%アナリストカバレッジGood最終更新日13 Apr 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 27Nanosonics Limited to Report First Half, 2026 Results on Feb 24, 2026Nanosonics Limited announced that they will report first half, 2026 results on Feb 24, 2026お知らせ • Jan 20Nanosonics Limited Appoints Sarah Butler as Independent Non-Executive Director and Member of Innovation and Development Committee, Effective January 19, 2026Nanosonics Limited has appointed Sarah Butler as an independent non-executive director, effective from January 19, 2026. Sarah Butler brings 35 years of diverse expertise in supporting organizations across regulated sectors to achieve global growth, scale their impact and improve diversity and inclusion. Throughout her career, she has specialised in strategic consulting, serving as a partner at Booz Allen Hamilton, Booz & Company and most recently at PwC, where she led PwC’s AUD 2 billion Global Health practice through the COVID-19 pandemic. At Booz & Company, she held several senior positions, including Global Insurance Leader and Managing Director for Greater China. Sarah Butler currently serves as an independent non-executive director of Australian Clinical Labs, Lumonus, a private healthtech SaaS company, and health research institute The George Institute for Global Health, where she is Chair of the People & REM Committee. She is also a director of Insurance Manufacturers of Australia Pty Limited (IMA), a joint venture between IAG and RACV focused on personal insurance. Previously, Sarah Butler was a director at Booz & Company, where she chaired the Audit & Risk Committee, and at PwC Australia. She is an FAICD and was a scholar at the University of Cambridge, United Kingdom, where she received a Bachelor of Arts (Hons) and a Master of Arts in Natural Sciences (Chemistry). Sarah Butler will serve as a member of Nanosonics’ Innovation and Development Committee.お知らせ • Nov 07Nanosonics Limited (ASX:NAN) announces an Equity Buyback for AUD 20 million worth of its shares.Nanosonics Limited (ASX:NAN) announces an share repurchase program. Under the program, the company will repurchases up to $20 million worth of its shares. The program will valid till November 4, 2026. As of November 5, 2025, the company had 304,164,829 shares in issue.お知らせ • Sep 05Nanosonics Limited, Annual General Meeting, Nov 05, 2025Nanosonics Limited, Annual General Meeting, Nov 05, 2025.お知らせ • Aug 07Nanosonics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Nanosonics Limited announced that they will report fiscal year 2025 results on Aug 26, 2025お知らせ • Jan 23Nanosonics Limited to Report First Half, 2025 Results on Feb 20, 2025Nanosonics Limited announced that they will report first half, 2025 results on Feb 20, 2025お知らせ • Jan 14Nanosonics Limited Appoints Gerard Dalbosco as an Independent Non-Executive Director, Effective 14 January 2025Nanosonics Limited announced the appointment of Gerard Dalbosco as an Independent Non-Executive Director of Nanosonics, effective 14 January 2025. Mr. Dalbosco brings extensive experience to the Company. He had a distinguished executive career, most notably at EY, where he held a number of senior leadership roles spanning multiple regions and functions, including Oceania Managing Partner and CEO, Asia Pacific Joint Deputy CEO, and Oceania Managing Partner - Transaction Advisory Services. Prior to these roles, he was instrumental in advising clients across a range of industries, focusing on mergers and acquisitions, financial due diligence, and commercial strategy. Beyond his corporate career, Gerard has broad governance experience. He is currently a Director at Medibank Private Ltd. and serves as Chair of Melbourne Archdiocese Catholic Schools. He is also Chair of the Gillespie Family Council & Gillespie Family Foundation (founders/owners of Bakers Delight). Previous governance roles include Mercy Health & Aged Care (Director and Chair of Finance and Audit Committee), Berry Street Victoria (Director and Member of Finance Committee) and the Committee for Melbourne (Director, Deputy Chair and Chair of Finance, Audit and Risk). Gerard is a Fellow of the Institute of Chartered Accountants in Australia, a Graduate of the Australian Institute of Company Directors and holds a Bachelor of Commerce and Masters in Applied Finance from Melbourne University. Gerard will be a member of both the Audit & Risk Committee and the People, Safety, and Remuneration Committee. It is expected that Mr. Dalbosco will assume the role of Chairman of the Audit & Risk Committee following the release of the first half of fiscal year 2025 accounts.お知らせ • Oct 18Nanosonics Limited Announces Board RetirementsNanosonics Limited provided an update in respect of its Board renewal process. The Company confirms that David Fisher has indicated that he intends to not seek re-election at this year's AGM on 12 November 2024. Dr. Fisher has been a member of the Board since July 2001 and has made a longstanding and significant contribution to the Company during his tenure including as Chair of the Innovation & Development Committee for many years, and interim CEO for a period. The Company also confirmed that Geoff Wilson has indicated that he intends to not seek re-election at this year's AGM on 12 November 2024. Mr. Wilson has made a significant contribution to the Company both as Chair of the Audit & Risk Committee and as a valued Non-Executive Director since joining the Board 5 years ago.お知らせ • Sep 24Nanosonics Limited, Annual General Meeting, Nov 12, 2024Nanosonics Limited, Annual General Meeting, Nov 12, 2024. Location: at nanosonics head office at level 1, building a,7-11 talavera road, macquarie park nsw 2113, Australiaお知らせ • Jul 15Nanosonics Limited to Report Fiscal Year 2024 Results on Aug 27, 2024Nanosonics Limited announced that they will report fiscal year 2024 results on Aug 27, 2024お知らせ • Jan 23+ 1 more updateNanosonics Limited to Report First Half, 2024 Results on Feb 26, 2024Nanosonics Limited announced that they will report first half, 2024 results on Feb 26, 2024お知らせ • Sep 07Nanosonics Limited Announces Appointment of Jason Burriss as Chief Financial Officer, Effective 3 October 2023Nanosonics Limited announced the appointment of Jason Burriss as Chief Financial Officer (CFO), effective 3 October 2023. Jason is an experienced Chief Financial Officer with a 25-year career spanning healthcare, financial services, and construction over four continents. Jason performed senior finance roles with General Electric (GE) for 15 years, notably CFO for GE Healthcare Australia & New Zealand. More recently, Jason held several international CFO roles for the Hilti Group over 6 years. During this time, Jason built the return-on-investment strategy for South Asia Pacific before relocating from Singapore to Dubai to focus on growth with distribution partners across more than 50 countries in the Middle East, Turkey, and Africa. Jason holds a Bachelor of Commerce from the University of Western Sydney, is a member of the Institute of Chartered Accountants Australia and New Zealand and attained executive education in Strategic Financial Analysis from Harvard Business School, USA.お知らせ • Aug 25Nanosonics Limited Appoints Larry Marshall as Non- Executive Director, Effective from 3 October 2023Nanosonics Limited announced the appointment of Dr. Larry Marshall as a Non- executive Director of Nanosonics effective 3 October 2023. Dr. Marshall brings significant experience to the Company. Dr. Marshall is a technology innovator, physicist and business leader with over 30 years' experience in leadership of technology companies. He has founded companies and driven innovation in Silicon Valley and Australia. Until July 2023, Dr. Marshall was Chief Executive of CSIRO for 8½ years. Under his stewardship CSIRO doubled the value delivered to stakeholders, achieved a record $1.6 Billion in revenue, enjoyed the first sustained growth in 30 years, and became the first Australian entity to be Thompson Reuters rated in the Global Top 20 Innovation organisations. Dr. Marshall lived in the United States for 26 years, where he co-founded 6 successful companies in a range of markets including medical device. Over the past 30 years he has served as CEO/MD of 6 companies, and Chairman of 4. He was MD, then co-Chairman of Arasor, a developer and manufacturer of integrated optical and wireless solutions, which he took public in 2006. In 2007, Dr. Marshall became MD of Southern Cross Venture Partners, a Silicon Valley VC firm specialising in Australian innovation. Dr. Marshall holds a PhD in Physics, and a Bachelor of Science (Hons) from Macquarie University. He is a Fellow of the AICD, ATSE, AIP, and a Federation Fellow. He has been a director of 20 private sector boards in Australia and the United States, including boards of 2 companies that were subsequently listed on the Nasdaq and on the ASX respectively.お知らせ • Aug 22Nanosonics Limited, Annual General Meeting, Nov 03, 2023Nanosonics Limited, Annual General Meeting, Nov 03, 2023, at 11:00 E. Australia Standard Time. Location: Nanosonics Office Level 1 Building A, 7-11 Talavera Road, Macquarie Park New South Wales Australiaお知らせ • Aug 03Nanosonics Limited to Report Fiscal Year 2023 Results on Aug 22, 2023Nanosonics Limited announced that they will report fiscal year 2023 results on Aug 22, 2023お知らせ • Jul 21Nanosonics Limited Announces the Appointment of Tracey Batten as Non-Executive Director, Effective 26 September 2023Nanosonics Limited announced the appointment of Dr. Tracey Batten as a Non-executive Director of Nanosonics effective 26 September 2023. Dr. Batten brings to Nanosonics a wealth of experience in the healthcare sector gained in both non-executive and executive roles, as well as medical practitioner and clinical roles, over more than 30 years. During her executive career, Dr. Batten was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent's Health Australia, CEO of Eastern Health, CEO of Dental Health Services Victoria and held various other clinical and medical leadership roles. Dr. Batten holds a Bachelor of Medicine/Bachelor of Surgery from the University of Melbourne, a Master of Health Administration from the University of New South Wales, and an MBA from Harvard Business School. Dr. Batten is currently a non-executive director of Medibank Private Ltd, the EBOS Group Limited, the Accident Compensation Corporation and the National Institute of Water and Atmospheric Research. In addition, Dr. Batten was previously non-executive director of Abano Healthcare Group Ltd. and various other healthcare related research institutes, charities and industry and government bodies.お知らせ • May 12+ 1 more updateNanosonics Announces Company Secretary ChangesNanosonics announced the resignation of Company Secretary, McGregor Grant after 12 years in the role. Mr. Matthew Carbines, General Counsel, and member of the Executive team has been appointed as Company Secretary effectively immediately.お知らせ • Feb 15Nanosonics Limited to Report First Half, 2023 Results on Feb 23, 2023Nanosonics Limited announced that they will report first half, 2023 results on Feb 23, 2023業績と収益の成長予測OTCPK:NNCS.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202825031273886/30/202723023183086/30/2026211171222812/31/2025207212429N/A9/30/2025203213037N/A6/30/2025199213544N/A3/31/2025191193139N/A12/31/2024184172835N/A9/30/2024177152429N/A6/30/2024170132023N/A3/31/2024167142123N/A12/31/2023164162224N/A9/30/2023165182124N/A6/30/2023166202023N/A3/31/2023154151520N/A12/31/2022141101016N/A9/30/20221317511N/A6/30/2022120407N/A3/31/2022120727N/A12/31/20211211148N/A9/30/20211121058N/A6/30/2021103967N/A3/31/202199779N/A12/31/2020956810N/A9/30/20209781516N/A6/30/2020100102123N/A3/31/202096111618N/A12/31/201992121113N/A9/30/20198813N/A9N/A6/30/20198414N/A5N/A3/31/20197812N/A6N/A12/31/20187111N/A6N/A9/30/2018668N/A8N/A6/30/2018616N/A9N/A3/31/2018616N/A11N/A12/31/2017616N/A13N/A9/30/20176416N/A15N/A6/30/20176826N/A16N/A3/31/20176526N/A16N/A12/31/20166325N/A16N/A9/30/20165313N/A10N/A6/30/2016430N/A3N/A3/31/201633-5N/A-3N/A12/31/201523-10N/A-8N/A9/30/201523-8N/A-5N/A6/30/201522-5N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NNCS.Fの予測収益成長率 (年間21.2% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: NNCS.Fの収益 ( 21.2% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。高成長収益: NNCS.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: NNCS.Fの収益 ( 8.6% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: NNCS.Fの収益 ( 8.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NNCS.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 11.9 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 14:53終値2026/05/15 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nanosonics Limited 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Josh KannourakisBarrenjoey Markets Pty LimitedJohn HesterBell PotterLyanne HarrisonBofA Global Research11 その他のアナリストを表示
お知らせ • Jan 27Nanosonics Limited to Report First Half, 2026 Results on Feb 24, 2026Nanosonics Limited announced that they will report first half, 2026 results on Feb 24, 2026
お知らせ • Jan 20Nanosonics Limited Appoints Sarah Butler as Independent Non-Executive Director and Member of Innovation and Development Committee, Effective January 19, 2026Nanosonics Limited has appointed Sarah Butler as an independent non-executive director, effective from January 19, 2026. Sarah Butler brings 35 years of diverse expertise in supporting organizations across regulated sectors to achieve global growth, scale their impact and improve diversity and inclusion. Throughout her career, she has specialised in strategic consulting, serving as a partner at Booz Allen Hamilton, Booz & Company and most recently at PwC, where she led PwC’s AUD 2 billion Global Health practice through the COVID-19 pandemic. At Booz & Company, she held several senior positions, including Global Insurance Leader and Managing Director for Greater China. Sarah Butler currently serves as an independent non-executive director of Australian Clinical Labs, Lumonus, a private healthtech SaaS company, and health research institute The George Institute for Global Health, where she is Chair of the People & REM Committee. She is also a director of Insurance Manufacturers of Australia Pty Limited (IMA), a joint venture between IAG and RACV focused on personal insurance. Previously, Sarah Butler was a director at Booz & Company, where she chaired the Audit & Risk Committee, and at PwC Australia. She is an FAICD and was a scholar at the University of Cambridge, United Kingdom, where she received a Bachelor of Arts (Hons) and a Master of Arts in Natural Sciences (Chemistry). Sarah Butler will serve as a member of Nanosonics’ Innovation and Development Committee.
お知らせ • Nov 07Nanosonics Limited (ASX:NAN) announces an Equity Buyback for AUD 20 million worth of its shares.Nanosonics Limited (ASX:NAN) announces an share repurchase program. Under the program, the company will repurchases up to $20 million worth of its shares. The program will valid till November 4, 2026. As of November 5, 2025, the company had 304,164,829 shares in issue.
お知らせ • Sep 05Nanosonics Limited, Annual General Meeting, Nov 05, 2025Nanosonics Limited, Annual General Meeting, Nov 05, 2025.
お知らせ • Aug 07Nanosonics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Nanosonics Limited announced that they will report fiscal year 2025 results on Aug 26, 2025
お知らせ • Jan 23Nanosonics Limited to Report First Half, 2025 Results on Feb 20, 2025Nanosonics Limited announced that they will report first half, 2025 results on Feb 20, 2025
お知らせ • Jan 14Nanosonics Limited Appoints Gerard Dalbosco as an Independent Non-Executive Director, Effective 14 January 2025Nanosonics Limited announced the appointment of Gerard Dalbosco as an Independent Non-Executive Director of Nanosonics, effective 14 January 2025. Mr. Dalbosco brings extensive experience to the Company. He had a distinguished executive career, most notably at EY, where he held a number of senior leadership roles spanning multiple regions and functions, including Oceania Managing Partner and CEO, Asia Pacific Joint Deputy CEO, and Oceania Managing Partner - Transaction Advisory Services. Prior to these roles, he was instrumental in advising clients across a range of industries, focusing on mergers and acquisitions, financial due diligence, and commercial strategy. Beyond his corporate career, Gerard has broad governance experience. He is currently a Director at Medibank Private Ltd. and serves as Chair of Melbourne Archdiocese Catholic Schools. He is also Chair of the Gillespie Family Council & Gillespie Family Foundation (founders/owners of Bakers Delight). Previous governance roles include Mercy Health & Aged Care (Director and Chair of Finance and Audit Committee), Berry Street Victoria (Director and Member of Finance Committee) and the Committee for Melbourne (Director, Deputy Chair and Chair of Finance, Audit and Risk). Gerard is a Fellow of the Institute of Chartered Accountants in Australia, a Graduate of the Australian Institute of Company Directors and holds a Bachelor of Commerce and Masters in Applied Finance from Melbourne University. Gerard will be a member of both the Audit & Risk Committee and the People, Safety, and Remuneration Committee. It is expected that Mr. Dalbosco will assume the role of Chairman of the Audit & Risk Committee following the release of the first half of fiscal year 2025 accounts.
お知らせ • Oct 18Nanosonics Limited Announces Board RetirementsNanosonics Limited provided an update in respect of its Board renewal process. The Company confirms that David Fisher has indicated that he intends to not seek re-election at this year's AGM on 12 November 2024. Dr. Fisher has been a member of the Board since July 2001 and has made a longstanding and significant contribution to the Company during his tenure including as Chair of the Innovation & Development Committee for many years, and interim CEO for a period. The Company also confirmed that Geoff Wilson has indicated that he intends to not seek re-election at this year's AGM on 12 November 2024. Mr. Wilson has made a significant contribution to the Company both as Chair of the Audit & Risk Committee and as a valued Non-Executive Director since joining the Board 5 years ago.
お知らせ • Sep 24Nanosonics Limited, Annual General Meeting, Nov 12, 2024Nanosonics Limited, Annual General Meeting, Nov 12, 2024. Location: at nanosonics head office at level 1, building a,7-11 talavera road, macquarie park nsw 2113, Australia
お知らせ • Jul 15Nanosonics Limited to Report Fiscal Year 2024 Results on Aug 27, 2024Nanosonics Limited announced that they will report fiscal year 2024 results on Aug 27, 2024
お知らせ • Jan 23+ 1 more updateNanosonics Limited to Report First Half, 2024 Results on Feb 26, 2024Nanosonics Limited announced that they will report first half, 2024 results on Feb 26, 2024
お知らせ • Sep 07Nanosonics Limited Announces Appointment of Jason Burriss as Chief Financial Officer, Effective 3 October 2023Nanosonics Limited announced the appointment of Jason Burriss as Chief Financial Officer (CFO), effective 3 October 2023. Jason is an experienced Chief Financial Officer with a 25-year career spanning healthcare, financial services, and construction over four continents. Jason performed senior finance roles with General Electric (GE) for 15 years, notably CFO for GE Healthcare Australia & New Zealand. More recently, Jason held several international CFO roles for the Hilti Group over 6 years. During this time, Jason built the return-on-investment strategy for South Asia Pacific before relocating from Singapore to Dubai to focus on growth with distribution partners across more than 50 countries in the Middle East, Turkey, and Africa. Jason holds a Bachelor of Commerce from the University of Western Sydney, is a member of the Institute of Chartered Accountants Australia and New Zealand and attained executive education in Strategic Financial Analysis from Harvard Business School, USA.
お知らせ • Aug 25Nanosonics Limited Appoints Larry Marshall as Non- Executive Director, Effective from 3 October 2023Nanosonics Limited announced the appointment of Dr. Larry Marshall as a Non- executive Director of Nanosonics effective 3 October 2023. Dr. Marshall brings significant experience to the Company. Dr. Marshall is a technology innovator, physicist and business leader with over 30 years' experience in leadership of technology companies. He has founded companies and driven innovation in Silicon Valley and Australia. Until July 2023, Dr. Marshall was Chief Executive of CSIRO for 8½ years. Under his stewardship CSIRO doubled the value delivered to stakeholders, achieved a record $1.6 Billion in revenue, enjoyed the first sustained growth in 30 years, and became the first Australian entity to be Thompson Reuters rated in the Global Top 20 Innovation organisations. Dr. Marshall lived in the United States for 26 years, where he co-founded 6 successful companies in a range of markets including medical device. Over the past 30 years he has served as CEO/MD of 6 companies, and Chairman of 4. He was MD, then co-Chairman of Arasor, a developer and manufacturer of integrated optical and wireless solutions, which he took public in 2006. In 2007, Dr. Marshall became MD of Southern Cross Venture Partners, a Silicon Valley VC firm specialising in Australian innovation. Dr. Marshall holds a PhD in Physics, and a Bachelor of Science (Hons) from Macquarie University. He is a Fellow of the AICD, ATSE, AIP, and a Federation Fellow. He has been a director of 20 private sector boards in Australia and the United States, including boards of 2 companies that were subsequently listed on the Nasdaq and on the ASX respectively.
お知らせ • Aug 22Nanosonics Limited, Annual General Meeting, Nov 03, 2023Nanosonics Limited, Annual General Meeting, Nov 03, 2023, at 11:00 E. Australia Standard Time. Location: Nanosonics Office Level 1 Building A, 7-11 Talavera Road, Macquarie Park New South Wales Australia
お知らせ • Aug 03Nanosonics Limited to Report Fiscal Year 2023 Results on Aug 22, 2023Nanosonics Limited announced that they will report fiscal year 2023 results on Aug 22, 2023
お知らせ • Jul 21Nanosonics Limited Announces the Appointment of Tracey Batten as Non-Executive Director, Effective 26 September 2023Nanosonics Limited announced the appointment of Dr. Tracey Batten as a Non-executive Director of Nanosonics effective 26 September 2023. Dr. Batten brings to Nanosonics a wealth of experience in the healthcare sector gained in both non-executive and executive roles, as well as medical practitioner and clinical roles, over more than 30 years. During her executive career, Dr. Batten was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent's Health Australia, CEO of Eastern Health, CEO of Dental Health Services Victoria and held various other clinical and medical leadership roles. Dr. Batten holds a Bachelor of Medicine/Bachelor of Surgery from the University of Melbourne, a Master of Health Administration from the University of New South Wales, and an MBA from Harvard Business School. Dr. Batten is currently a non-executive director of Medibank Private Ltd, the EBOS Group Limited, the Accident Compensation Corporation and the National Institute of Water and Atmospheric Research. In addition, Dr. Batten was previously non-executive director of Abano Healthcare Group Ltd. and various other healthcare related research institutes, charities and industry and government bodies.
お知らせ • May 12+ 1 more updateNanosonics Announces Company Secretary ChangesNanosonics announced the resignation of Company Secretary, McGregor Grant after 12 years in the role. Mr. Matthew Carbines, General Counsel, and member of the Executive team has been appointed as Company Secretary effectively immediately.
お知らせ • Feb 15Nanosonics Limited to Report First Half, 2023 Results on Feb 23, 2023Nanosonics Limited announced that they will report first half, 2023 results on Feb 23, 2023